SYNTHESIS OF ETOPOSIDE PHOSPHATE, BMY-40481 - A WATER-SOLUBLE CLINICALLY ACTIVE PRODRUG OF ETOPOSIDE

被引：35

作者：

SAULNIER, MG

LANGLEY, DR

KADOW, JF

SENTER, PD

KNIPE, JO

TUN, MM

VYAS, DM

DOYLE, TW

机构：

[1] Bristol-Myers Squibb Company, Wallingford, CT 06492

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 1994年 / 4卷 / 21期

关键词：

D O I：

10.1016/S0960-894X(01)80285-7

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Etoposide Phosphate (BMY-40481) is synthesized semisynthetically from the clinically approved anticancer parent drug, etoposide (VP-16-213), and also from natural (-)-epipodophyllotoxin. Etoposide phosphate functions as a clinically active, water soluble prodrug of etoposide. The NDA for etoposide phosphate was filed in June, 1994.

引用

页码：2567 / 2572

页数：6

共 15 条

[1] BUNDGAARD H, 1985, DESIGN PRODRUGS
[2] CISPLATIN PLUS ETOPOSIDE CONSOLIDATION FOLLOWING CYCLOPHOSPHAMIDE, DOXORUBICIN, AND VINCRISTINE IN LIMITED SMALL-CELL LUNG-CANCER
EINHORN, LH
CRAWFORD, J
BIRCH, R
OMURA, G
JOHNSON, DH
GRECO, FA
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (03) : 451 - 456
[3] Issel B. F., 1984, ETOPOSIDE VP 16 CURR
[4] ISSELL BF, 1982, CANCER CHEMOTH PHARM, V7, P73
[5] ACUTE TOXICITY AND LIMITS OF SOLVENT RESIDUE FOR 16 ORGANIC SOLVENTS
KIMURA, ET
EBERT, DM
DODGE, PW
[J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 1971, 19 (04) : 699 - &
[6] MITOSIS INHIBITING NATURAL SUBSTANCES .22. PARTIAL SYNTHESIS OF 4'-DEMETHYLEPIPODOPHYLLOTOXIN
KUHN, M
KELLERJU.C
VONWARTB.A
[J]. HELVETICA CHIMICA ACTA, 1969, 52 (04) : 944 - &
[7] HISTAMINE-RELEASING PROPERTIES OF POLYSORBATE-80 INVITRO AND INVIVO - CORRELATION WITH ITS HYPOTENSIVE ACTION IN THE DOG
MASINI, E
PLANCHENAULT, J
PEZZIARDI, F
GAUTIER, P
GAGNOL, JP
[J]. AGENTS AND ACTIONS, 1985, 16 (06): : 470 - 477
[8] MILLWARD MJ, 1992, 7TH P NCI EORTC S NE, P146
[9] ROSE WC, 1990, INVEST NEW DRUG, V8, pS25
[10] RYAN RP, 1993, 93605 BRIST MYERS SQ

← 1 2 →